Otsenka effektivnosti i perenosimosti abiraterona atsetata (Zitiga) u patsientov s metastaticheskim gormonorezistentnym rakom predstatel'noy zhelezy, u kotorykh otmechalas' progressiya opukholevogo protsessa posle khimioterapii taksanami


Cite item

Full Text

Abstract

References

  1. Ferlay J, Shin HR, Bray F et al. GLOBOCAN. Cancer incidence and mortality worldwide: IARC Cancer Base 2008; 10.
  2. Давыдов М.И., Аксель Е.М. Вестник РОНЦ им. Н.Н.Блохина (Прил. 1). 2011; 22 (3): 13-4.
  3. Anderson J. Treatment of prostate cancer - the role of primary hormonal therapy. EAU Update (Series 1) 2003; p. 32-9.
  4. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-20.
  5. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12.
  6. Hellerstedt B, Pienta KJ. Prostate cancer and the geriatric patient. In: Principles of geriatric medicine and gerontology (5th ed.).
  7. Goshman L, Fish J, Roller K. Clinically significant cytochrome P-450 drug interactions. J Pharm Soc Wis 1999; p. 23-38.
  8. Mohler JL, Gregory CW, Ford OH et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004; 10: 440-8.
  9. Stigliano et al. Increased metastatic lymph node 64 and CYP17 expression are associated with high stage prostate cancer. J Endocrinol 2007; 194: 55-61.
  10. Gregory CW, Hamil KG, Kim D et al. Androgen receptor expression in androgen independent prostate cancer is associated with increased expression of androgen regulated genes. Cancer Res 1998; 58: 5718-24.
  11. Labrie F, Cusan L, Gomez JL et al. Long-term combined androgen blockade alone for localized prostate cancer. Molecular Urology 1999; 3: 217-25.
  12. Ryan C, Smith M, Fong L et al. Phase I clinical trial of CYP17 ingibitor abiraterona acetate demonstrating clinical activity in patient with castration-resistant prostate cancer who received prior ketoconasole therapy. J Clin Oncol 2010; 28: 1481-8.
  13. Danila D, Morris M, de Bono J et al. Phase II multicenter study of abiraterona acetate plus prednisone therapy in with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 2010; 28: 1496-501.
  14. Reid A, Attard G, Danila D et al. Significant and sustained antitumor activate in post docetaxel, castration-resistant prostate cancer with CYP17 ingibitor abiraterona acetate. J Clin Oncol 2010; 286: 1489-95.
  15. De Bono et al. The New English J Med 2011; 21: 364.
  16. Attard G et al. Phase I clinical trial of a selective inhibitor of CYP17. Abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone. JCO 2008; p. 4563-71.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 69203 от 24.03.2017 г. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 63964 от 18.12.2015 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies